DRUG DISCOVERY

DRUG DISCOVERY

DATA INTEGRITY

GLOBAL COMPLIANCE

QUALITY ASSURANCE

DRUG DISCOVERY AND DEVELOPMENT PROCESS

To find and develop active pharmaceutical compounds that are safe, effective, and suitable for manufacture, requires a surprising breadth of research and investigation. According to the current state of chemical and biological sciences utilized for pharmaceutical development, some 5,000–10,000 chemical compounds have passed through laboratory screening for each new medicine licensed for human use.

Around 250 of the 5,000–10,000 compounds examined will go into preclinical research, and 5 will go into clinical testing. The entire process of developing a medicine, from discovery to marketing, can take 10 to 15 years. This section introduces the typical flow of the discovery process for New Molecular Entities (NMEs) within the pharmaceutical industry.

The Discovery of NMEs results from the efforts of a diverse group of public and commercial entities involved in the development and manufacturing of active pharmaceutical ingredients (APIs) and drug products. Many publicly financed institutions do basic research in fields including chemistry, biochemistry, physiology, microbiology, and pharmacology as part of this process.

Rather than focusing on the production of a product or technology, basic research typically aims to gain a better knowledge of natural chemicals or physiological processes. This allows researchers at both public and private institutions to apply this fundamental knowledge to the discovery of new NMEs matched to specific metabolic pathways or protein targets.

Scientists and medics working in a range of research institutions and universities perform the first steps in this procedure. Their findings are published in peer-reviewed scientific and medical journals. These findings aid in the identification of potential new targets for NME development related to specific disease states. A drug receptor, an enzyme, a biological transport route, or any other mechanism engaged in body metabolism could be suitable targets.

Almost all of the complex biochemical operations in the human body and within all of our cells are controlled by enzymes. Characterization of the three-dimensional enzyme structure and key active sites on the enzyme are major NME discovery and structure-based drug design components. High-throughput protein structure determination enables the screening of large numbers of candidate NMEs and significantly reduces discover timelines.

Once suitable targets and NMEs have been identified, Pharmaceutical corporations carry out or direct the majority of the remaining work involved in drug research and development.

Rigaku offers a range of screens, instrumentation, and software to enable and facilitate the drug discovery process. From protein crystallization kits and screens to high-throughput protein and small-molecule crystal structure elucidation, Rigaku leads the way. With innovative small-angle X-ray scattering (SAXS) systems specifically designed for automated protein analysis and unique pair distribution function (PDF) methods for small molecules, Rigaku supports the future of drug discovery.

Myoglobin

 

117788_RAH_PharmalyticalSummit_Accelevent_700x350Logo_R2

A DAY OF EDUCATION AND INSIGHTS FOR PHARMACEUTICAL PROFESSIONALS THROUGHOUT THE PRODUCT DEVELOPMENT LIFECYCLE 

Pharmalytical Summit 2021 is a one-day virtual event exploring the technologies, analysis, and innovation that goes into bringing the pharmaceuticals allowing humanity to live longer, fuller, healthier lives.


The day features presentations and discussions with industry leaders and experts who share insights and education to help bring these life-changing products into the world.

 

Join us on May 26th, 2021 from 8 AM to 8 PM CDT.

DISCOVERY AGENDA

RELATED APPLICATIONS

The Use of Atomic Pair Distribution Function Analysis to Verify Molecular Structure for Amorphous Materials

Small Angle X-ray Scattering Approaches for Pharmaceutical Studies

Thermal Analysis for Pharmaceutical Applications

A Non-Destructive XRF Technique for Rapid and Easy Screening of Residual Catalysts in API's & Intermediates

INDUSTRY-LEADING SUPPORT

OUR COMMITMENT TO CUSTOMERS

  • 24/7 PHONE SUPPORT
  • IQ/OQ/PQ PROGRAM
  • SOP DEVELOPMENT
    CONTACT SERVICE

MADE IN THE USA

FOCUSED CUSTOMER SUPPORT

RECOMMENDED PRODUCT

PROGENY HANDHELD 1064 nm Raman

Progeny Polysorbate Result-resized-B

Versatile Spectrometer for Raw Material Identification and Verification

LEARN MORE

CUTTING-EDGE TECHNOLOGY

HANDHELD 1064 nm RAMAN SPECTROSCOPY

FEATURES & BENEFITS

  • NONDESTRUCTIVE
  • ANALYZE SOLIDS, LIQUIDS, POWDERS, GELS, PASTES AND MORE
  • SCAN THROUGH COLORED PACKAGING
  • ANALYZE COLORED SUBSTANCES
  • RESULTS < 1 MINUTE
  • MINIMIZED FLUORESCENCE

HOW WE WORK WITH YOU

Videos_Icon From Rigaku Global Site

1 - SEE HOW IT WORKS

LIVE AND RECORDED VIRTUAL DEMOS AVAILABLE

GET A DEMO
Sale_Icon

2 - REQUEST A QUOTE

MULTI-UNIT DISCOUNTS AVAILABLE

GET A QUOTE
Handshake_Icon

3 - PURCHASE

PAYMENTS ACCEPTED: 
CREDIT CARD
BANK TRANSFER
PURCHASE ORDER 

SUBMIT NOW

TRUSTED PARTNER

Based in Wilmington, Massachusetts, USA since 2011, Rigaku is a pioneer in handheld 1064 nm Raman and LIBS-based technology for materials analysis. With thousands of units in use globally, our portfolio offers the most versatile solution for use in safety and security against chemical threats, pharmaceutical manufacturing, and in the recycling and quality control of metal alloys. 

We strive to deliver quality, reliability and engaged expertise to our customers. We are dedicated to continuous product development efforts to deliver mission-critical enhancements to performance and functionality, while delivering reliable and cost-effective solutions for results, anywhere.

Rigaku Analytical Devices is an ISO 9001:2015 certified facility.

RAD_Overview_MASTER_YouTube1080p